Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label Trial of Bortezomib (VELCADE®) in Combination With Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT01633645 is registered in ClinicalTrials.gov with University Hospital of Crete as lead sponsor.

NCT NCT01633645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01633645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label Trial of Bortezomib (VELCADE®) in Combination With Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lead sponsor
University Hospital of Crete
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2009
Completion date
April 30, 2013
Enrollment
53 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic, non small cell lung cancer